Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

NCT00132067 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer

Interventions

DRUG: vorinostat

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]